Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Bleomycin, Etoposide, and Cisplatin in Treating Patients With Metastatic Germ Cell Cancer of the Testicles

Phase 3

Completed

Conditions: Testicular Germ Cell Tumor
Drug/Agent Toxicity by Tissue/Organ

First Posted Date: 2006-05-11

Last Posted Date: 2013-08-12

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 210

Registration Number: NCT00324298

Locations: 🇬🇧
Saint Bartholomew's Hospital, London, England, United Kingdom
🇬🇧
University College of London Hospitals, London, England, United Kingdom
🇬🇧
Ipswich Hospital, Ipswich, England, United Kingdom

and more 7 locations

A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.

Phase 1

Completed

Conditions: Acute Lymphoblastic Leukemia
Acute Myelogenous Leukemia
Relapsed Leukemia

Interventions: Drug: clofarabine
Drug: Etoposide
Drug: Cyclophosphamide

First Posted Date: 2006-04-19

Last Posted Date: 2014-04-14

Lead Sponsor: Genzyme, a Sanofi Company

Target Recruit Count: 50

Registration Number: NCT00315705

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

and more 10 locations

Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma

Phase 2

Withdrawn

Conditions: AIDS-related Lymphoma
Adult Non-Hodgkin's Lymphoma
Anaplastic Large Cell Lymphoma

First Posted Date: 2006-04-03

Last Posted Date: 2016-02-03

Lead Sponsor: AIDS Malignancy Consortium

Registration Number: NCT00310128

Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors

Phase 1

Completed

Conditions: Anaplastic Oligoastrocytoma
Anaplastic Oligodendroglioma
Mixed Glioma
Oligoastrocytoma

Interventions: Drug: Carboplatin
Drug: Etoposide
Drug: Etoposide Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mannitol
Drug: Melphalan
Other: Quality-of-Life Assessment
Drug: Sodium Thiosulfate

First Posted Date: 2006-03-17

Last Posted Date: 2022-03-17

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 33

Registration Number: NCT00303849

Locations: 🇺🇸
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

Phase 2

Completed

Conditions: Neurofibromatosis Type 1
Sarcoma

Interventions: Biological: filgrastim
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2006-03-17

Last Posted Date: 2018-09-18

Lead Sponsor: Sarcoma Alliance for Research through Collaboration

Target Recruit Count: 48

Registration Number: NCT00304083

Locations: 🇺🇸
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States

and more 14 locations

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

Phase 1

Completed

Conditions: Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

Interventions: Biological: anti-thymocyte globulin
Biological: sargramostim
Drug: busulfan
Drug: etoposide
Drug: fludarabine phosphate
Drug: prednisone
Drug: tacrolimus
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: umbilical cord blood transplantation

First Posted Date: 2006-03-17

Last Posted Date: 2013-08-14

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 5

Registration Number: NCT00304018

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Phase 3

Completed

Conditions: Stage III Adrenal Cortical Carcinoma AJCC v7
Stage I Adrenal Cortical Carcinoma AJCC v7
Stage II Adrenal Cortical Carcinoma AJCC v7
Stage IV Adrenal Cortical Carcinoma AJCC v7

Interventions: Procedure: Conventional Surgery
Drug: Cisplatin
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Biological: Filgrastim
Drug: Mitotane
Biological: Pegfilgrastim

First Posted Date: 2006-03-17

Last Posted Date: 2024-02-28

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 78

Registration Number: NCT00304070

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada

and more 88 locations

Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Infants With Neuroblastoma

Not Applicable

Conditions: Neuroblastoma

First Posted Date: 2006-02-07

Last Posted Date: 2013-09-17

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 120

Registration Number: NCT00287950

Locations: 🇬🇧
Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom
🇬🇧
Leicester Royal Infirmary, Leicester, England, United Kingdom
🇮🇪
Our Lady's Hospital for Sick Children, Dublin, Ireland

and more 18 locations

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

Phase 2

Terminated

Conditions: Unusual Cancers of Childhood
Chronic Myeloproliferative Disorders
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Leukemia
Lymphoma

Interventions: Biological: filgrastim
Biological: anti-thymocyte globulin
Drug: cyclophosphamide
Drug: busulfan
Drug: carmustine
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: methotrexate
Drug: cytarabine
Drug: mycophenolate mofetil
Drug: etoposide
Drug: methylprednisolone
Drug: tacrolimus
Drug: melphalan
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy
Procedure: umbilical cord blood transplantation

First Posted Date: 2006-01-25

Last Posted Date: 2017-09-27

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 200

Registration Number: NCT00281879

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas

Phase 3

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: cisplatin
Drug: etoposide
Drug: ifosfamide
Drug: lomustine
Drug: methotrexate
Drug: prednisone
Drug: vincristine sulfate

First Posted Date: 2006-01-18

Last Posted Date: 2013-12-19

Lead Sponsor: German Society for Pediatric Oncology and Hematology GPOH gGmbH

Target Recruit Count: 150

Registration Number: NCT00278278

Locations: 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy